COMMUNIQUÉS West-GlobeNewswire
 
      -   
  Helsinn Group and MEI Pharma Report Correlation between Mutations in DNA Methylation Pathway and Clinical Response in Phase II Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia05/06/2017
-   
  Silmäasema Oyj's public offering has been oversubscribed and the subscription period discontinued05/06/2017
-   
  Novartis announces ground-breaking collaboration with IBM Watson Health on outcomes-based care in advanced breast cancer05/06/2017
-   
  Summit Presents Positive New Preclinical Data on Novel CDI Antibiotic Ridinilazole at ASM Microbe 201705/06/2017
-   
  Immunocore Announces Compelling Single Agent IMCgp100 Clinical Data in Metastatic Uveal Melanoma at ASCO 2017 Annual Meeting05/06/2017
-   
  Nexstim Plc Members of the Board Committees05/06/2017
-   
  Michael Phelps, World Champion Athlete and Mental Health Advocate, Appointed to Medibio Board of Directors05/06/2017
-   
  Innate Pharma acquiert l'anti-C5aR, un anticorps en Phase clinique, auprès de Novo Nordisk A/S02/06/2017
-   
  Souris dans l'espace : des souris de Taconic incluses dans le lancement vers la Station spatiale internationale02/06/2017
-   
  Virbac : Déclaration d'actions et de droits de vote au 31 Mai 201702/06/2017
-   
  Virbac : Declaration of the number of shares and voting rights as of May 2017, 31.02/06/2017
-   
  XBiotech présente des résultats de phase III pour son traitement par anticorps du cancer colorectal lors de la réunion ASCO de 201702/06/2017
-   
  Nexstim Plc Agrees on Extension of Tekes R&D Loan Repayments02/06/2017
-   
  Crown Bioscience affiche une maîtrise approfondie des modèles PDX et une expertise émergente en immuno-oncologie02/06/2017
-   
  Orion Diagnostica's co-operation negotiations in Oulu completed02/06/2017
-   
  Zealand to present at two international healthcare investor conferences in June 201702/06/2017
-   
  Tecan appoints Erik Norström Head of Corporate Development02/06/2017
-   
  Novartis presents updated data that reinforce the efficacy and safety of Kisqali® (ribociclib) plus letrozole as a first-line option for HR+/HER2- advanced or metastatic breast cancer02/06/2017
-   
  Basilea names new member of its Extended Management Committee02/06/2017
Pages